PF-04620110

Product Name: PF-04620110
CAS No.: 1109276-89-2
Chemical Name: PF-04620110
Synonyms: CS-1117;PF-04620110;PF-04620110 USP/EP/BP;PF 04620110; PF04620110;2-(trans-4-(4-(4-Amino-5-oxo-7,8-dihydropyrimido[5,4-f]-[1,4]oxazepin-6(5H)-yl)phenyl)cyclohex;2-[4-[4-(4-Amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6-yl)phenyl]cyclohexyl]acetic acid;2-(trans-4-(4-(4-Amino-5-oxo-7,8-dihydropyrimido[5,4-f]-[1,4]oxazepin-6(5H)-yl)phenyl)cyclohexyl);2-(4-(4-(4-aMiNA-5-oxo-7,8-dihydropyriMido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl)cyclohexyl)acetic acid;trans-4-[4-(4-Amino-7,8-dihydro-5-oxopyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]cyclohexaneacetic acid;2-(trans-4-(4-(4-Amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl)cyclohexyl)acetic acid
CBNumber: CB52534577
Molecular Formula: C21H24N4O4
Formula Weight: 396.44
MOL File: 1109276-89-2.mol

More

Less

PF-04620110 Property

Boiling point:: 701.9±60.0 °C(Predicted)
Density: 1.326
storage temp.: room temp
solubility: DMSO: soluble10mg/mL (clear solution)
pka: 4.72±0.10(Predicted)
form: powder
color: white to beige

More

Less

Safety

Hazard Codes: Xn
Risk Statements: 22
WGK Germany: 3

More

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

Precautionary statements

P280Wear protective gloves/protective clothing/eye protection/face protection.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More

Less

N-Bromosuccinimide Price

Sigma-Aldrich

Product number: PZ0207
Product name: PF-04620110
Purity: ≥98% (HPLC)
Packaging: 5mg
Price: $127
Updated: 2024/03/01

Sigma-Aldrich

Product number: PZ0207
Product name: PF-04620110
Purity: ≥98% (HPLC)
Packaging: 25mg
Price: $505
Updated: 2024/03/01

Cayman Chemical

Product number: 16425
Product name: PF-04620110
Purity: ≥98%
Packaging: 5mg
Price: $92
Updated: 2024/03/01

Cayman Chemical

Product number: 16425
Product name: PF-04620110
Purity: ≥98%
Packaging: 10mg
Price: $155
Updated: 2024/03/01

Cayman Chemical

Product number: 16425
Product name: PF-04620110
Purity: ≥98%
Packaging: 25mg
Price: $360
Updated: 2024/03/01

More

Less

PF-04620110 Chemical Properties,Usage,Production

Uses

PF 04620110 is an orally-active, inhibitor that has selectivity towards neutral-diglyceride acyltransferase-1 (DGAT-1).

Biological Activity

pf-04620110 is a potent, selective and orally-bioavailable inhibitor of diacylglycerol acyltransferase 1 (dgat-1), an enzyme catalyzing the final committed step in the biosynthesis of triglycerides, that inhibits dgat-1 with values of 50% inhibition concentration ic50 of 19 nm and 8 nm in human and ht-29 cells respectively. pf-04620110 displays a highly selective, more than 100 fold, inhibition against dgat-1 rather than a range of lipid processing enzymes, including human dgat-2, human acyl-coa:cholesterol acyltransferase 1, human acyl-coa:wax alcohol acyltransferase 1, human acyl-coa:wax alcohol acyltransferase 2, human acyl-coa:monacylglycerol acyltransferase 2, human acyl-coa:monacylglycerol acyltransferase 3 and mouse mgat 1.lee kr, choi sh, song js, seo h, chae yj, cho he, ahn jh, ahn sh, bae ma. determination of pf-04620110, a novel inhibitor of diacylglycerol acyltransferase-1, in rat plasma using liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic studies. biomed chromatogr. 2013; 27(7):846-852.robert l. dow *, jian-cheng li , michael p. pence , e. michael gibbs , jennifer l. laperle , john litchfield , david w. piotrowski , michael j. munchhof , tara b. manion , william j. zavadoski , gregory s. walker , r. kirk mcpherson , susan tapley , eliot sugarman , angel guzman-perez , and paul dasilva-jardine discovery of pf-04620110, a potent, selective, and orally bioavailable inhibitor of dgat-1. acs med. chem. lett., 2011, 2 (5), pp 407–412

Biochem/physiol Actions

PF-04620110 is known to regulate gut hormones. Inhibition of DGAT1 might serve as a good approach for the treatment of obesity and type 2 diabetes. DGAT1 inhibition might increase the oxidation of fatty acids, thus it is found to be protective against hepatic steatosis.

target

DGAT-1

storage

Store at +4°C

PF-04620110 Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

PF-04620110 Suppliers

China 52 United Kingdom 1 United States 16 Global 69

Shanghai Boyle Chemical Co., Ltd.

Tel
Fax: 86-21-57758967
Email: sales@boylechem.com
Country: China
ProdList: 2923
Advantage: 55

Chembest Research Laboratories Limited

Tel: 021-20908456
Fax: 021-58180499
Email: sales@BioChemBest.com
Country: China
ProdList: 6011
Advantage: 61

Accendatech Co., LTD.

Tel: 13132578992
Fax: 022-83718543-802
Email: sales@accendatech.com
Country: China
ProdList: 332
Advantage: 58

Haoyuan Chemexpress Co., Ltd.

Tel: 021-58950125
Fax: (86) 21-58955996
Email: info@chemexpress.com
Country: China
ProdList: 7553
Advantage: 61

Shanghai Aladdin Bio-Chem Technology Co.,LTD

Tel: 18521735133 18521732826;
Fax: 021-50323701
Email: market@aladdin-e.com
Country: China
ProdList: 25015
Advantage: 65

MedChemexpress LLC

Tel: 021-58955995
Fax: 609-228-5909
Email: sales@medchemexpress.cn
Country: United States
ProdList: 4863
Advantage: 58

Guangzhou Isun Pharmaceutical Co., Ltd

Tel: 020-39119399 18927568969
Fax: 020-39119999
Email: isunpharm@qq.com
Country: China
ProdList: 4428
Advantage: 55

LETOPHARM LIMITED

Tel: +86-21-5821 5861
Fax: +86-21-5106 2861
Email: sales@letopharm.com
Country: China
ProdList: 2384
Advantage: 58

Sigma-Aldrich

Tel: 021-61415566 800-8193336
Email: orderCN@merckgroup.com
Country: China
ProdList: 51471
Advantage: 80

SPIRO PHARMA

Tel
Fax: -
Email: eric_feng1954@126.com
Country: China
ProdList: 9254
Advantage: 55

More

Less

View Lastest Price from PF-04620110 manufacturers

Career Henan Chemical Co

Product: PF-04620110 1109276-89-2
Price: US $2.00/kg
Min. Order: 1kg
Purity: 99%
Supply Ability: 100kg
Release date: 2018-12-23

1109276-89-2, PF-04620110Related Search:

TENOVIN-1 Bortezomib Enzalutamide Nilotinib IWP-2 Olaparib

Cyclohexaneacetic acid, 4-[4-(4-amino-7,8-dihydro-5-oxopyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]-, trans-

PF 04620110; PF04620110

CS-1117

2-((1r,4r)-4-(4-(4-aMino-5-oxo-7,8-dihydropyriMido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl)cyclohexyl)acetic acid

2-(4-(4-(4-aMiNA-5-oxo-7,8-dihydropyriMido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl)cyclohexyl)acetic acid

2-(trans-4-(4-(4-Amino-5-oxo-7,8-dihydropyrimido[5,4-f]-[1,4]oxazepin-6(5H)-yl)phenyl)cyclohexyl)

2-(trans-4-(4-(4-Amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl)cyclohexyl)acetic acid

2-[4-[4-(4-Amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6-yl)phenyl]cyclohexyl]acetic acid

2-(trans-4-(4-(4-Amino-5-oxo-7,8-dihydropyrimido[5,4-f]-[1,4]oxazepin-6(5H)-yl)phenyl)cyclohex

PF-04620110

trans-4-[4-(4-Amino-7,8-dihydro-5-oxopyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]cyclohexaneacetic acid

PF-04620110 USP/EP/BP

1109276-89-2

Inhibitors